Algorae Pharmaceuticals Limited (ASX:1AI)

Market Cap	8.44M
Revenue (ttm)	125.20K
Net Income (ttm)	-1.30M
Shares Out	1.69B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,373
Average Volume	846,888
Open	0.0060
Previous Close	0.0060
Day's Range	0.0060 - 0.0060
52-Week Range	0.0050 - 0.0130
Beta	0.45
RSI	43.55
Earnings Date	Apr 23, 2025

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company’s product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer’s disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 48
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: 1AI

Financial Performance

In 2024, Algorae Pharmaceuticals's revenue was 125,200, an increase of 197.98% compared to the previous year's 42,016. Losses were -2.10 million, -0.57% less than in 2023.